Oncogene

Aims & Scope

Oncogene aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research.

We propagate work that challenges standard conjecture and builds on previous studies, in particular those that lead to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers, and in processes that drive metastatic spread, and provide important insights into cancer biology beyond what has been revealed thus far.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	7.3
2024	6.90

SJR (SCImago Journal Rank)

Year	Value
2024	2.489

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	380

Journal Rank

Year	Value
2024	966

Journal Citation Indicator

Year	Value
2024	8748

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Activators and target genes of Rel/NF-κB transcription factors

  Citation: 3289

  Authors: Heike L

• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  Citation: 2660

  Authors: Zahid H

• MAP kinase signalling pathways in cancer

  Citation: 2416

  Authors: A S, S, O, W

• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  Citation: 2257

  Authors: P J, C J

• Molecular mechanisms of cisplatin resistance

  Citation: 2174

  Authors: L, L, I, J, I, O, M, G

• Wnt signaling in cancer

  Citation: 2123

  Authors: T, N, M

• EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

  Citation: 2106

  Authors: A, J

• The tumor microenvironment and its role in promoting tumor growth

  Citation: 1918

  Authors: T L

• Introduction to NF-κB: players, pathways, perspectives

  Citation: 1856

  Authors: T D

• MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer

  Citation: 1843

  Authors: Ping, Sven, Wenbing, Sebastian, Ralf, Paul M, Nicola, Burkhard, Horst, Etmar, Michael, Wolfgang E, Hubert, Carsten

---